Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report) had its price objective reduced by research analysts at The Goldman Sachs Group from $28.00 to $24.00 in a research note issued to investors on ...

Biogen (NASDAQ:BIIB – Get Free Report) had its price target decreased by research analysts at The Goldman Sachs Group from $281.00 to $245.00 in a research note issued to investors on ...

More stable investment management and net interest income could cause investors to reassess Goldman's earnings quality and increase their willingness to pay a premium for it.

Goldman Sachs CEO David Solomon was awarded an $80 million stock bonus to stay at the helm for another five years, a stark turnaround for a leader whose survival was questioned after the firm's ...

Bank of America Securities analyst Ebrahim Poonawala maintained a Buy rating on Goldman Sachs Group (GS – Research Report) today. The company’s ...

We recently published a list of 10 Worst Performing Bank Stocks in 2024. In this article, we are going to take a look at ...

We recently published a list of 10 Worst Performing Bank Stocks in 2024. In this article, we are going to take a look at ...

The Chinese startup’s offering could trigger what economists call the Jevons paradox, by removing the barrier to entry to ...

Another potential implication is a stronger dollar, which would further hurt S&P 500 earnings because the companies get 28% ...

We recently published a list of Jim Cramer Discussed 10 Stocks Leading the Dow Higher in 2025. In this article, we are going ...

Goldman Sachs (GS) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the ...

In a report released today, Rajan Sharma from Goldman Sachs maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price ...